2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4265 Impact of pre-transplant measurable residual disease on relapse and survival following fludarabine-busulfan-melphalan conditioning for acute myeloid leukemia

Jieling Jiang, MD,PhD, Wenhui Gao, MD2, ling Wang3, Lining WANG, MD4, Jiong Hu, MD5
1 Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine., Shanghai, Shanghai, China
2 Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine., Shanghai, Shanghai, China
3 Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine., Shanghai, Shanghai, China
4 Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine., Shanghai, Shanghai, China
5 Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine., Shanghai, Shanghai, China

Background:? We previously reported a low cumulative incidence of relapse (approximately 5%) in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a fludarabine-busulfan-melphalan (FBM) conditioning regimen. However, the prognostic impact of pre-transplant measurable residual disease (MRD) within this specific context remains undefined.
Methods:? We retrospectively analyzed 175 patients with AML who underwent first allo-HSCT in complete remission (CR) using the FBM regimen. The FBM protocol consisted of fludarabine 150 mg/m², busulfan 6.4 mg/kg, and melphalan 140 mg/m²; patients aged >55 years and/or with a Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) ≥3 received a reduced melphalan dose of 100 mg/m². MRD was measured by flow cytometry, with a positive threshold set at 0.01%. Patients were categorized by pre-transplant flow MRD status (MRD-negative, n=132; MRD-positive, n=43) and stratified by the Disease Risk Index (DRI) of HSCT (low risk, n=31; intermediate risk, n=112; high risk, n=32). Overall survival (OS), leukemia-free survival (LFS), and event-free survival (EFS)—with events defined as non-relapse mortality (NRM), molecular relapse, or hematologic relapse—were estimated using the Kaplan-Meier method, with intergroup comparisons performed using the log-rank test. Cumulative incidences of NRM, molecular relapse (mCIR), and hematologic relapse (hCIR) were calculated using competing risks models and compared using Gray’s test.
Results:? The median age of the whole chort was 46 years (range, 15 to 67 years) and the median follow-up was 1,262 days (range, 212–2,363 days) for survivors. MRD positivity was associated with non-significant trends toward inferior 3-year OS (73.2% vs. 82.7%, P=0.380) and LFS (74.3% vs. 81.0%, P=0.397). Similarly, MRD-positive patients demonstrated a trend toward reduced EFS (64.5% vs. 74.9%, P=0.176). Competing risks analysis revealed significantly higher 3-year cumulative incidences of mCIR (28.1% vs. 11.2%, P=0.005) and hCIR (17.7% vs. 4.0%, P=0.012) in the MRD-positive cohort. Furthermore, MRD positivity led to a dramatic increase in the 3-year mCIR rate (52.3% vs. 19.8%, P=0.003) in the DRI-high subgroup; a similar trend was observed in the DRI-intermediate subgroup (21.3% vs. 8.7%, P=0.019), whereas no significant MRD-related difference in mCIR was observed in the DRI-low subgroup (20.0% vs. 9.5%, P=0.434). Regarding hCIR, MRD positivity significantly elevated relapse risk in both the DRI-high (46.4% vs. 15.7%, P=0.029) and DRI-intermediate subgroups (13.8% vs. 1.5%, P=0.024). Notably, no hematologic relapses occurred in the DRI-low cohort irrespective of MRD status. The 3-year cumulative incidence of NRM did not differ significantly between the MRD-positive and MRD-negative groups (9.6% vs. 15.5%, P=0.352).
Conclusion:? Pre-transplant MRD positivity is a potent predictor of disease recurrence following FBM conditioning, with its deleterious effect being exponentially amplified in patients with high DRI scores. These findings underscore the necessity for intensified monitoring and early interventional strategies for MRD-positive patients, particularly those classified as DRI-high or intermediate risk.

Jieling Jiang, MD,PhD: No relevant conflicts of interest to declare.